Loading
A phase 3 trial of Durvalumab, Cisplatin and Capecitabine in oesophageal cancer, run by AstraZeneca, active and no longer recruiting.
Study of Durvalumab Versus Placebo in Combination With Definitive Chemoradiation Therapy in Patient With ESCC is a phase 3 interventional study registered as NCT04550260 by AstraZeneca, with 640 participants enrolled, started 2020-10-19 and due to reach its primary completion in 2027-06-30. Interventions recorded: Durvalumab, Placebo, cisplatin + fluorouracil, cisplatin + capecitabine and Radiation.
Shares Oesophageal squamous cell carcinoma, Oesophageal cancer, Cisplatin, Immune checkpoint inhibitors and the tag pipeline.
Shares Oesophageal squamous cell carcinoma, Oesophageal cancer, Cisplatin and the tag pipeline.
Shares Oesophageal squamous cell carcinoma, Oesophageal cancer, Cisplatin, Immune checkpoint inhibitors and the tag pipeline.
Shares Durvalumab, AstraZeneca, Immune checkpoint inhibitors and the tag pipeline.
Shares Durvalumab, AstraZeneca, Cisplatin, Immune checkpoint inhibitors and the tag pipeline.
Shares Durvalumab, AstraZeneca, Immune checkpoint inhibitors and the tag pipeline.
Shares Durvalumab, AstraZeneca, Cisplatin, Immune checkpoint inhibitors and the tag pipeline.
Shares Durvalumab, AstraZeneca, Cisplatin, Immune checkpoint inhibitors and the tag pipeline.